title: Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
abstract: OBJECTIVE
  The aim of this research was to determine the influence of bifurcation lesions on the outcome of patients undergoing percutaneous coronary intervention (PCI) in the recent era.
  
  
  BACKGROUND
  The treatment of bifurcation lesions by PCI has been associated with an increased complication rate. Whether recent improvements of interventional practice have translated into improved outcomes in this patient subgroup is unknown.
  
  
  METHODS
  The 11,482 patients enrolled in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) were stratified according to the presence (n = 1,412) or absence (n = 10,068) of at least one bifurcation lesion treated by PCI. Baseline characteristics and outcome of patients undergoing PCI for bifurcation lesions were compared to those of patients treated for nonbifurcation lesions.
  
  
  RESULTS
  Patients treated for bifurcation lesions were less likely to have prior myocardial infarction (MI), prior coronary artery bypass graft surgery, and had a higher proportion of current stable angina (p < 0.01 for all comparisons). Bifurcation lesions involved more frequently the left anterior descending coronary artery and were more complex (angulated, eccentric, ostial, and tortuous) than nonbifurcation lesions. Percutaneous coronary intervention of bifurcation lesions was characterized by less frequent stent implantation (71% vs. 80%); PCI of bifurcation lesions was associated with an increased rate of combined end point death/MI/target vessel revascularization (TVR) at nine months (18% vs. 15%, p = 0.002) because of increased rates of TVR (17% vs. 14%, p < 0.001), whereas death (1%) and MI (1%) were not different between groups.
  
  
  CONCLUSIONS
  Percutaneous coronary intervention of bifurcation lesions is associated with higher TVR at follow-up. However, the risk of death, MI, death/MI was similar in patients treated for bifurcation or nonbifurcation lesions.
authors.affiliation: Institut Cardio-vasculaire Paris Sud, Quincy, France. p.garot@icps.com.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Garot
authors.forename: Thierry
authors.initials: T
authors.lastname: Lefèvre
authors.forename: Michael
authors.initials: M
authors.lastname: Savage
authors.forename: Yves
authors.initials: Y
authors.lastname: Louvard
authors.forename: William R
authors.initials: WR
authors.lastname: Bamlet
authors.forename: James T
authors.initials: JT
authors.lastname: Willerson
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Morice
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
chemical_list: D062367:ortho-Aminobenzoates; C012293:tranilast